Search Result
Results for "
recombinant-human-alpha-crystallin-b-chain-cryab-his
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-150097
-
|
Biochemical Assay Reagents
|
Others
|
Recombinant Human Serum Albumin (rHSA) is an active compound and possesses an identical conformation to plasma derived HSA. Recombinant Human Serum Albumin (rHSA) has no difference between rHSA and plasma derived HSA. Recombinant Human Serum Albumin (rHSA) has high efficacy of rHSA with little or no adverse reaction .
|
-
-
- HY-101979A
-
CB-1158 dihydrochloride; INCB01158 dihydrochloride
|
Arginase
|
Cancer
|
Numidargistat (CB-1158) dihydrochloride is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent .
|
-
-
- HY-101979
-
CB-1158; INCB01158
|
Arginase
|
Cancer
|
Numidargistat (CB-1158) is a potent and orally active inhibitor of arginase, with IC50s of 86 nM and 296 nM for recombinant human arginase 1 and recombinant human arginase 2, respectively. Immuno-oncology agent .
|
-
-
- HY-P1068A
-
|
Bacterial
|
Infection
|
Recombinant human lysozyme (plant expression) is a conserved anti-bacterial protein that causes bacterial lysis and death by hydrolyzing bacterial cell wall peptidoglycan (PG). Recombinant human lysozyme (plant expression) can be used to study bacterial infections .
|
-
-
- HY-P4062
-
BIL
|
Insulin Receptor
|
Metabolic Disease
|
Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins .
|
-
-
- HY-P4890
-
-
-
- HY-P4890A
-
-
-
- HY-103189
-
-
-
- HY-15314
-
AS-3201
|
Aldose Reductase
|
Neurological Disease
Metabolic Disease
|
Ranirestat (AS-3201) potent and orally active aldose reductase (AR) inhibitor with IC50s of 11 nM and 15 nM for rat lens AR and recombinant human AR, respectively, and a Ki of 0.38 nM for recombinant human AR. Ranirestat has the potential for diabetic sensorimotor polyneuropathy treatment. Ranirestat also has a neuroprotective effect on diabetic retinas .
|
-
-
- HY-P10204
-
|
Wnt
|
Cancer
|
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
|
-
-
- HY-12199
-
-
-
- HY-12199B
-
-
-
- HY-112998
-
|
Factor VIII
|
Others
|
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
|
-
-
- HY-101601
-
-
-
- HY-12199A
-
-
-
- HY-19303
-
|
|
|
CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ) .
|
-
-
- HY-19303A
-
-
-
- HY-19303B
-
-
-
- HY-P3479
-
-
-
- HY-103483
-
-
-
- HY-108828
-
rhGAA
|
Others
|
Others
|
Alglucosidase alfa is a hydrolytic lysosomal glycogen-specific recombinant human α-glucosidase product. Alglucosidase alfa can be used for Pompe disease research .
|
-
-
- HY-16040
-
|
LPL Receptor
|
Inflammation/Immunology
|
AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
|
-
-
- HY-101383
-
|
Sodium Channel
|
Neurological Disease
|
PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker with an IC50 of 196 nM for recombinant human Nav1.8 channel.
|
-
-
- HY-10397A
-
MX1013
2 Publications Verification
CV1013; Z-VD-FMK
|
Caspase
|
Cancer
|
MX1013 is a potent, irreversible dipeptide caspase inhibitor vith antiapoptotic activity. MX1013 inhibits recombinant human caspase 3 with an IC50 of 30 nM .
|
-
-
- HY-109530
-
|
Others
|
Metabolic Disease
|
Insulin lispro is a recombinant human insulin analogue and is one of three rapid-acting insulin analogues available. Insulin lispro can be used for the research of hyperglycaemia in diabetes mellitus .
|
-
-
- HY-N0518
-
|
PAI-1
|
Cardiovascular Disease
|
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM .
|
-
-
- HY-P99693
-
GC1102
|
HBV
|
Infection
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .
|
-
-
- HY-122154
-
|
Adenosine Deaminase
|
Inflammation/Immunology
|
FR234938 is a non-nucleoside adenosine deaminase inhibitor with an IC50 of 17 nM for recombinant human adenosine deaminase enzyme. FR234938 has anti-rheumatic and anti-inflammatory effects .
|
-
-
- HY-108830
-
Aryplase; BM-102
|
Others
|
Metabolic Disease
|
Galsulfase (Aryplase, BM-102) is recombinant human N-acetylgalactosamine-4-sulfatase. Galsulfase (Aryplase, BM-102) can be used for mucopolysaccharidosis (MPS) research .
|
-
-
- HY-P99262
-
BAX69; Anti-human MIF recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
-
- HY-P99288
-
Pamrevlumab; Anti-human CTGF recombinant Antibody
|
Apoptosis
|
Cancer
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
|
-
-
- HY-P99785
-
HLX20
|
PD-1/PD-L1
|
Cancer
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
-
-
- HY-P99337
-
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
-
- HY-P99889
-
BRII-198
|
SARS-CoV
|
Infection
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
-
- HY-13862
-
AZD1080
5 Publications Verification
|
GSK-3
|
Neurological Disease
|
AZD1080 is a potent and selective GSK3 inhibitor. AZD1080 inhibits recombinant human GSK3α and GSK3β with pKi (IC50) of 8.2 (6.9 nM) and 7.5 (31 nM), respectively.
|
-
-
- HY-122168
-
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
AAT-008 is a potent, selective, and orally active prostaglandin EP4 receptor antagonist with Kis of 0.97 and 6.1 nM for recombinant human EP4 and recombinant rat EP4, respectively .
|
-
-
- HY-P3533
-
|
Integrin
|
Cardiovascular Disease
|
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .
|
-
-
- HY-15556
-
GSK 269962
|
ROCK
|
Cardiovascular Disease
Inflammation/Immunology
|
GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities .
|
-
-
- HY-15556A
-
GSK 269962 hydrochloride
|
ROCK
|
Cardiovascular Disease
Inflammation/Immunology
|
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities .
|
-
-
- HY-P99952
-
SCT400
|
CD20
|
Cancer
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
|
-
-
- HY-P99792
-
NM57; rhRIG
|
RABV
|
Infection
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
-
- HY-14950
-
JTT-705; RO4607381
|
CETP
|
Cardiovascular Disease
Cancer
|
Dalcetrapib (JTT-705) is an orally active cholesteryl ester transfer protein (CETP) inhibitor with IC50s of 204.6 nM and 6 μM against recombinant human (rh) CETP and human plasma CETP, respectively .
|
-
-
- HY-133148
-
|
Phospholipase
|
Inflammation/Immunology
|
Lp-PLA2-IN-2 is a potent and selective lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 0f 120 nM for recombinant human Lp-PLA2 .
|
-
-
- HY-133149
-
|
Phospholipase
|
Cardiovascular Disease
|
Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2) .
|
-
-
- HY-19958
-
|
|
|
XEN907 is a potent and spirooxindole blocker of NaV1.7, with an IC50 of 3 nM. XEN907 also inhibits CYP3A4 in a recombinant human enzyme assay. XEN907 can be used for the research of pain .
|
-
-
- HY-100405
-
|
|
|
FTIDC is an orally active, noncompetitive, selective allosteric metabotropic glutamate receptor (mGluR) 1 antagonist with an IC50 of 5.8 nM for human mGluR1a. FTIDC has no species differences in its antagonistic activity on recombinant human, mouse, and rat mGluR1 .
|
-
-
- HY-103226
-
|
Aminopeptidase
|
Inflammation/Immunology
|
SC-57461A is a potent, orally active, nonpeptide, and selective inhibitor of Leukotriene A4 (LTA4) hydrolase with IC50s of 2.5 nM, 3 nM, and 23 nM for recombinant human, mouse, and rat LTA4 hydrolase, respectively .
|
-
-
- HY-P99908
-
NT-17
|
Interleukin Related
|
Cancer
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
-
-
- HY-19843
-
|
|
|
MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes .
|
-
-
- HY-108905
-
human IGF-I; FK 780
|
IGF-1R
|
Metabolic Disease
|
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
|
-
- HY-113482
-
1β-OH-DCA
|
Endogenous Metabolite
Cytochrome P450
|
Metabolic Disease
|
1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .
|
-
- HY-147389
-
|
Phosphodiesterase (PDE)
|
Cancer
|
Enpp-1-IN-14 (Compound 015) is a potent Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) inhibitor with an IC50 value of 32.38 nM for recombinant human ENPP-1. Enpp-1-IN-14 has anti-tumor activity .
|
-
- HY-108858
-
rhDNase
|
Others
|
Others
|
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA. Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions. Dornase alfa plays an important role in cystic fibrosis .
|
-
- HY-P99756
-
MEDI8897
|
RSV
|
Infection
|
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research .
|
-
- HY-N9892
-
|
Sirtuin
|
Others
|
Guttiferone G inhibits recombinant human SIRT1 and SIRT2 (IC50: 9 and 22 μM, respectively). Guttiferone G is weakly cytotoxic in A2780 human ovarian cell line (IC50: 8.0 μg/mL). Guttiferone G can be isolated from Garcinia macrophylla .
|
-
- HY-119744
-
|
Cannabinoid Receptor
|
Neurological Disease
|
BAY 38-7271 is selective and highly potent and cannabinoid CB1/CB2 receptor agonist, with Kis of 1.85 nM and 5.96 nM for recombinant human CB1 receptor and CB2 receptor, respectively. BAY 38-7271 has strong neuroprotective properties .
|
-
- HY-P99178
-
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
-
- HY-P9920
-
|
VEGFR
|
Cancer
|
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .
|
-
- HY-P99688
-
AL001
|
Neurotensin Receptor
|
Cancer
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
-
- HY-108658
-
|
P2Y Receptor
|
Cardiovascular Disease
|
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity .
|
-
- HY-141699
-
|
Others
|
Metabolic Disease
|
FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively .
|
-
- HY-151111
-
|
Renin
|
Cardiovascular Disease
|
SPH3127 (DRI 18) is a novel, highly potent, and orally active direct renin inhibitor (recombinant human-renin IC50=0.4 nM, human plasma renin activity IC50=0.45 nM). SPH3127 shows antihypertensive effect and can be used in essential hypertension research .
|
-
- HY-151807
-
|
15-PGDH
|
Metabolic Disease
|
15-PGDH-IN-1 is a potent and orally active 15-PGDH inhibitior. 15-PGDH-IN-1 has inhibition activity against recombinant human 15-PGDH with an IC50 value of 3 nM. 15-PGDH-IN-1 can be used for the research of tissue repair and regeneration .
|
-
- HY-P99335
-
Anti-human IL17A recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
-
- HY-P5201S
-
|
Isotope-Labeled Compounds
|
Others
|
VTSEGAGLQLQK- 13C6, 15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .
|
-
- HY-P5201S1
-
|
Isotope-Labeled Compounds
|
Others
|
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
|
-
- HY-50906
-
|
mGluR
|
Neurological Disease
|
LY404039 is a potent, selective and orally active mGluR2 and mGluR3 agonist with Kis of 149 nM and 92 nM for recombinant human mGluR2 and mGluR3, respectively. LY404039 shows >100-fold selectivity for mGluR2/3 over other receptors/transproters. LY404039 has antipsychotic and anxiolytic effects .
|
-
- HY-13765
-
-
- HY-19843A
-
|
Glucokinase
|
Metabolic Disease
|
MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes .
|
-
- HY-101075
-
|
|
|
L-690330 is a competitive inhibitor of inositol monophosphatase (IMPase) with Kis of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 exhibits 10-fold more sensitive than mouse and rat IMPase .
|
-
- HY-101075A
-
|
Phosphatase
|
Others
|
L-690330 hydrate is a competitive inhibitor of inositol monophosphatase (IMPase) with Kis of 0.27 and 0.19 μM for recombinant human and bovine IMPase, 0.30 and 0.42 μM for human and bovine frontal cortex IMPase, respectively. L-690330 hydrate exhibits 10-fold more sensitive than mouse and rat IMPase .
|
-
- HY-142032
-
|
LPL Receptor
|
Inflammation/Immunology
|
RBM10-8 is irreversible inhibitor of recombinant human sphingosine-1-phosphate lyase (hS1PL) . Sphingosine-1-phosphate (S1P) is a sphingolipid (SL) that acts as a signaling molecule regulating diverse cellular processes such as cell proliferation and differentiation, angiogenesis, immune function, inflammation, and development .
|
-
- HY-P99618
-
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
-
- HY-145933
-
|
Glutaminase
|
Inflammation/Immunology
|
BJJF078 is an aminopiperidine derivative. BJJF078 is a potent inhibitor of recombinant human and mouse Transglutaminase enzyme (TG2) activity, IC50 values of 41 and 54 nM, respectively. BJJF078 also inhibits the close related enzyme TG1, with an IC50 of 0.16 μM. BJJF078 can be used for Multiple sclerosis (MS) research .
|
-
- HY-19644
-
GSK 2256294
|
Epoxide Hydrolase
|
Cardiovascular Disease
|
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease .
|
-
- HY-111551
-
FT113
1 Publications Verification
|
Fatty Acid Synthase (FASN)
|
Cancer
|
FT113 is a potent and orally active fatty acid synthase (FASN) inhibitor, with an IC50 of 213 nM for full-length recombinant human FASN enzyme. In cell-based assay, FT113 blocks FASN activity in BT474 cells (IC50, 90 nM). FT113 shows anti-proliferative activity, and exhibits anti-cancer activity both in vitro and in vivo .
|
-
- HY-P9920A
-
|
VEGFR
|
Cancer
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
-
- HY-10295A
-
|
Organoid
p38 MAPK
Autophagy
Apoptosis
|
Neurological Disease
Cancer
|
SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .
|
-
- HY-P99294
-
AMG 479; human Anti-IGF1R recombinant Antibody
|
IGF-1R
|
Cancer
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
-
- HY-10295
-
SB 202190
Maximum Cited Publications
80 Publications Verification
|
Organoid
p38 MAPK
Autophagy
Apoptosis
|
Neurological Disease
Cancer
|
SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
|
-
- HY-117639
-
|
Potassium Channel
|
Neurological Disease
|
AUT1 is a recombinant human Kv3 channel modulator. AUT1 modulates Kv3.1b and Kv3.2a channels in human recombinant with pEC50 values of 5.33 and 5.31 μM, respectively. AUT1 can be used for the research of disorders associated with dysfunction of inhibitory feedback in corticolimbic circuits, such as schizophrenia .
|
-
- HY-D0004
-
Azure B chloride
|
Monoamine Oxidase
|
Neurological Disease
|
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
-
- HY-P9931
-
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
- HY-P99588
-
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
- HY-13954
-
|
P2X Receptor
|
Neurological Disease
Inflammation/Immunology
|
A 839977 is a P2X7 selective antagonist; it blocks BzATP-evoked calcium influx at recombinant human, rat and mouse P2X7 receptors (IC50 values are 20 nM, 42 nM and 150 nM respectively) and reduces inflammatory and neuropathic pain in animal models; the antihyperalgesic effects of P2X7 receptor blockade are mediated by blocking the release of IL-1beta .
|
-
- HY-108632
-
|
PARP
|
Cancer
|
BYK204165 is a potent and selective PARP1 inhibitor. BYK204165 inhibits cell-free recombinant human PARP-1 (hPARP-1) with a pIC50 of 7.35 (pKi=7.05), and murine PARP-2 (mPARP-2) with a pIC50 of 5.38, respectively. BYK204165 displays 100-fold selectivity for PARP-1 .
|
-
- HY-16373
-
LNK-754; OSI-754
|
Farnesyl Transferase
|
Cancer
|
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL . CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-108810
-
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
-
- HY-N2692
-
|
Others
|
Cancer
|
6,8-Diprenylgenistein is an isoflavone compound isolated from Cudrania tricuspidata. 6,8-Diprenylgenistein has antimicrobial and anti-obesity activity. 6,8-Diprenylgenistein inhibits the proliferation, migration and tubular formation of HLMEC induced by recombinant human vascular endothelial growth factor-A. 6,8-Diprenylgenistein can be used to study new therapeutic drugs for the prevention and treatment of oral cancer metastasis .
|
-
- HY-13240
-
|
Beta-secretase
|
Neurological Disease
|
LY2886721 is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
|
-
- HY-13240A
-
|
Beta-secretase
|
Neurological Disease
|
LY2886721 hydrochloride is a potent, selective and orally active beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 20.3 nM for recombinant human BACE1. LY2886721 hydrochloride is selectivity against cathepsin D, pepsin, and renin, but lacking selectivity against BACE2 (IC50 of 10.2 nM). LY2886721 hydrochloride can across blood-brain barrier and has the potential for Alzheimer's disease treatment .
|
-
- HY-P99803
-
VAL-1221
|
Glucosidase
|
Others
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-149300
-
|
Cholinesterase (ChE)
|
Neurological Disease
|
SB-1436 is an Cholinesterase (ChE) inhibitor, inhibits acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and recombinant human acetylcholinesterase (rHuAChE) with IC50s of 0.176, 0.37 and 0.08 μM, respectively. SB-1436 inhibits AChE and BChE in a non-competitive manner with Kis of 0.046 and 0.115 μM, respectively. SB-1436 significantly stops the self-aggregation of Aβ, and can be used for neurological disease research .
|
-
- HY-120502
-
|
Lipoxygenase
Leukotriene Receptor
|
Inflammation/Immunology
|
5-LOX-IN-6 (compound 11a) is a direct and reversible inhibitor of 5-lipoxygenase (5-LO). 5-LOX-IN-6 inhibits 5-LO activity in human neutrophils and recombinant human 5-LO with IC50 values of 0.23 and 0.086 µM, respectively. 5-LOX-IN-6 prevents leukotriene biosynthesis. 5-LOX-IN-6 can be used for inflammatory and allergic disorders research .
|
-
- HY-P5982
-
|
Phosphatase
|
Neurological Disease
|
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .
|
-
- HY-19627
-
S-297995
|
Opioid Receptor
|
Neurological Disease
Metabolic Disease
|
Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
|
-
- HY-19627A
-
S-297995 tosylate
|
Opioid Receptor
|
Neurological Disease
Metabolic Disease
|
Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA) . Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors . Naldemedine can be used in opioid-induced constipation (OIC) research . Naldemedine tosylate is predicted to bind to 3CL pro encoded by SARS-CoV2 genome .
|
-
- HY-122026
-
PF-367
|
GSK-3
|
Neurological Disease
|
PF-04802367 (PF-367) is a highly selective GSK-3 inhibitor with an IC50 of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and GSK-3β) with IC50 values of 10.0 and 9.0 nM in mobility shift assays, respectively .
|
-
- HY-P99605
-
PRS 343
|
EGFR
TNF Receptor
|
Cancer
|
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D0004
-
Azure B chloride
|
Dyes
|
Azure B is a cationic dye and the major metabolite of Methylene blue. Azure B is used in making Azure eosin stains for blood smear staining. Azure B is a high-potency, selective and reversible inhibitor of monoamine oxidases (MAO)-A, with IC50s of 11 and 968 nM for recombinant human MAO-A and MAO-B, respectively. Azure B possesses significant antidepressant-like effects .
|
Cat. No. |
Product Name |
Type |
-
- HY-150097
-
|
Biochemical Assay Reagents
|
Recombinant Human Serum Albumin (rHSA) is an active compound and possesses an identical conformation to plasma derived HSA. Recombinant Human Serum Albumin (rHSA) has no difference between rHSA and plasma derived HSA. Recombinant Human Serum Albumin (rHSA) has high efficacy of rHSA with little or no adverse reaction .
|
-
- HY-E70001
-
|
Biochemical Assay Reagents
|
Recombinant Human Luteinizing Hormone is a recombinant form of Luteinizing hormone (human) (HY-P2293). Luteinizing hormone (human), a heterodimeric glycoprotein hormone produced by the pituitary gland (LH), plays key roles in human reproduction .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4062
-
BIL
|
Insulin Receptor
|
Metabolic Disease
|
Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins .
|
-
- HY-P4890
-
-
- HY-P4890A
-
-
- HY-P4066
-
|
Peptides
|
Cancer
|
Emfilermin is a recombinant human leukaemia inhibitory factor (LIF) that can be used in chemotherapy-induced peripheral neuropathy studies .
|
-
- HY-P10204
-
|
Wnt
|
Cancer
|
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. FZD7 antagonist 1 is an FZD7 antagonist that inhibits the wnt3a with IC50 value of 9.2 nM. FZD7 antagonist 1 blocks TcdB−FZD interaction via targeting FZD receptors .
|
-
- HY-P3479
-
-
- HY-P3533
-
|
Integrin
|
Cardiovascular Disease
|
EILEVPST is a recombinant human fibronectinderived low-molecular-weight peptide fragment. EILEVPST can promote cell type-specific α4 integrin-mediated adhesion. EILEVPST can be used for the research of thrombogenesis .
|
-
- HY-108905
-
human IGF-I; FK 780
|
IGF-1R
|
Metabolic Disease
|
Mecasermin (Human IGF-I; FK 780) is a recombinant human insulin-like growth factor I (IGF-I). Mecasermin has the potential for the study of the growth failure of growth hormone (GH) insensitivity caused by GH receptor defects or GH-inhibiting antibodies .
|
-
- HY-P5201S1
-
|
Isotope-Labeled Compounds
|
Others
|
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
|
-
- HY-P10014
-
-
- HY-P3432
-
|
Peptides
|
Others
|
DfTat is a dimer of the prototypical cell-penetrating peptide TAT. DfTat can deliver small molecules, peptides and proteins into live cells with a particularly high efficiency. DfTat labeled with the rhodamine can be used as a tracer for easy detection .
|
-
- HY-P5982
-
|
Phosphatase
|
Neurological Disease
|
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .
|
-
- HY-P10016
-
HS-20039; EPO-018B
|
Peptides
|
Endocrinology
|
Pegmolesatide(HS-20039; EPO-018B) a synthetic peptide-based erythropoiesis-stimulating agent, can be used for ??the study of anemia in chronic kidney disease .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99262
-
BAX69; Anti-human MIF recombinant Antibody
|
Macrophage migration inhibitory factor (MIF)
|
Cancer
|
Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer .
|
-
- HY-P99288
-
Pamrevlumab; Anti-human CTGF recombinant Antibody
|
Apoptosis
|
Cancer
|
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF) .
|
-
- HY-112935
-
BAX326; Coagulation Factor IX [recombinant]
|
Inhibitory Antibodies
|
Others
|
Nonacog alfa (BAX326) is a recombinant human factor IX that can be used for the research of haemophilia B .
|
-
- HY-112998
-
|
Factor VIII
|
Others
|
Efmoroctocog alfa is a recombinant human coagulation factor VIII-Fc fusion protein (rFVIIIFc) that can be used for the research of haemophilia A .
|
-
- HY-P99693
-
GC1102
|
HBV
|
Infection
|
Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection .
|
-
- HY-P99785
-
HLX20
|
PD-1/PD-L1
|
Cancer
|
Opucolimab is an anti-PD-L1 recombinant human monoclonal antibody. Opucolimab can be used to synthesis antibody agent conjugates. Opucolimab can be used for the research of advanced solid tumors .
|
-
- HY-P99337
-
Ansuvimab-zyk; mAb114
|
Filovirus
|
Infection
|
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. Ansuvimab binds to the glycoprotein on Zaire ebolavirus to block its entry into host cells .
|
-
- HY-P99889
-
BRII-198
|
SARS-CoV
|
Infection
|
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .
|
-
- HY-P99952
-
SCT400
|
CD20
|
Cancer
|
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
|
-
- HY-P99792
-
NM57; rhRIG
|
RABV
|
Infection
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
- HY-P99908
-
NT-17
|
Interleukin Related
|
Cancer
|
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4 + and CD8 + cells in both human and mice. Efineptakin alfa can be used for glioblastoma research .
|
-
- HY-P99458
-
CG 10639
|
Inhibitory Antibodies
|
Cancer
|
Balugrastim (CG 10639) is a novel long-acting recombinant granulocyte colony-stimulating factor (G-CSF) obtained by means of a genetic fusion between recombinant human serum albumin and granulocyte colony-stimulating factor. Balugrastim can be used for the research of breast cancer .
|
-
- HY-P99756
-
MEDI8897
|
RSV
|
Infection
|
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research .
|
-
- HY-P99178
-
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
CTX-471 is a fully human monoclonal antibody of CD137. CTX-471 has bind affinity for recombinant human, cynomolgus macaque CD137 and mouse CD137 with Kd values of 50 nM, 61 nM and 748 nM, respectively. CTX-471 can be used for the research of immunomodulation and cancer .
|
-
- HY-P9920
-
|
VEGFR
|
Cancer
|
Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab is also an angiogenesis inhibitor .
|
-
- HY-P99688
-
AL001
|
Neurotensin Receptor
|
Cancer
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research .
|
-
- HY-P99335
-
Anti-human IL17A recombinant Antibody
|
Interleukin Related
|
Inflammation/Immunology
|
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a recombinant human IgGκ monoclonal antibody that targets IL-17A and inhibits its interaction with the IL-17 receptor. Vunakizumab can be used to study autoimmune diseases such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis .
|
-
- HY-P99618
-
IBI-315; BH2950
|
EGFR
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
Fidasimtamab (IBI-315; BH2950) is a recombinant human IgG1 bispecific antibody that targets, binds and inhibits both HER2 and PD-1 and their downstream signalling pathways, and links PD-1 expressing T cells to HER2 expressing tumour cells. Fidasimtamab has potential immunosuppressive and antitumor activity .
|
-
- HY-P9920A
-
|
VEGFR
|
Cancer
|
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .
|
-
- HY-P99294
-
AMG 479; human Anti-IGF1R recombinant Antibody
|
IGF-1R
|
Cancer
|
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer .
|
-
- HY-P9931
-
CNTO 1959
|
Interleukin Related
|
Inflammation/Immunology
|
Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research .
|
-
- HY-P99588
-
MYO-029
|
TGF-β Receptor
|
Metabolic Disease
|
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
|
-
- HY-108810
-
Ilaris; ACZ 885
|
Interleukin Related
|
Inflammation/Immunology
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin .
|
-
- HY-P99803
-
VAL-1221
|
Glucosidase
|
Others
|
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research .
|
-
- HY-P99605
-
PRS 343
|
EGFR
TNF Receptor
|
Cancer
|
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (Kd=0.3 nM) and human monomeric CD137 (4-1BB; Kd=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-P5201S
-
|
VTSEGAGLQLQK- 13C6, 15N2 is the 13C and 15N labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA). VTSEGAGLQLQK can be used to bind anti-drug antibodies (ADA) in plasma and quantitatively analyze the therapeutic effect .
|
-
-
- HY-P5201S1
-
|
VTSEGAGLQLQK- 13C6, 15N2 (TFA) is the 13C- and 15N-labeled VTSEGAGLQLQK. VTSEGAGLQLQK is an amino acid sequence in the C-terminal region of recombinant human alpha-acid glucosidase (rhGAA), which can be used to bind anti-drug antibodies in plasma and quantitatively analyze the therapeutic effect .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-16373
-
LNK-754; OSI-754
|
|
Alkynes
|
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL . CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: